All In Biotech

Drug Trial Radar · NCT04848688

Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Efficacy and Safety of Moxidectin in Comparison to Ivermectin Against Strongyloides Stercoralis Infection in Adults: a Randomized Controlled Non-inferiority Trial

Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

332

Actual

Start

Feb 5, 2022

Primary completion

Jul 17, 2022

Study completion Jul 17, 2022

Sponsor

Lead sponsor
Jennifer KeiserAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Centre for Parasitology, Entomology and Malaria Control, Cambodia
First posted
Apr 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is an extension to the study StrongMoxi NCT04056325 and entails modifications based on the outcome of NCT04056325 part A. The study is a phase 3, double-blinded and randomized clinical trial conducted in Cambodia. It aims at providing evidence on efficacy, safety and pharmacokinetic measures of 8 mg of moxidectin compared to 200 μg/kg ivermectin in adults infected with S. stercoralis. The efficacy of the treatment will be assessed by collecting three stool samples once per-treatment and once 21-28 days post-treatment. The stool samples will be analyzed by a quantitative duplicate Baermann assay.

Conditions

  • Strongyloides Stercoralis Infection

Interventions

  • Moxidectin 2 mgDrug

    Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.

  • Ivermectin 3 mgDrug

    Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.

  • PlaceboDrug

    Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure Rate Against Strongyloides StercoralisTime frame: 14-21 days after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Centre for Parasitology, Entomology and Malaria Control

    Phnom Penh, Cambodia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.